Hi Eric,

You state you have no relation with Boeringer Ingleheim, producer of dabigatran.
Your policy (theheart.org):
"Disclosure
We disclose sources of funding and site contributors’ possible conflicts of interest."

You are Editor-in-Chief of all "theheart.org". As I understand it, this whole website is financed directly or indirectly mainly by money from the pharmaceutical industry.
Boeringer I. is one of the pharmaceutical companies paying for there special interest CME-event, disvcussions lead by Michael Weber or any other chairman pushing the most recent and most expensive alternative etc.

Can´t you, Eric J Topol, see any "possible conflict of interest" there? I can trust you anyway, I agree with you in most cases, but why say there is no potential for conflict of interests in your position as Editor-in-Chief?

If, a few years from now, dabigatran is an ordinary pill among others and the compliance of taking dabigatran regularly and strictly may be around 60-70% as it is for statins or antihypertensives. Because of monitoring warfarin compliance may be 95%. 95% compliance with warfarin or 60-70 % compliance of dabigatran, which will give the best stroke prevention do you think?

Anders Hernborg, M.D.
Halmstad, Sweden